The European Medicines Firm designates AbbVie’s (NYSE:ABBV) venetoclax an Orphan Medicine with the therapy of acute myeloid leukemia (AML).
Venetoclax, a little molecule inhibitor of a healthy protein telephoned B-cell lymphoma-2, is obtain co-produced with Roche (OTCQX:RHHBY).
Among the incentives of Orphan Medicine condition in Europe is a 10-year time period of supply exclusivity with the indication, if approved.
